Loriot, Y. Et Al. 2021. Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .

Loriot, Y., Alva, A. S., Csoszi, T., ÖZGÜROĞLU, M., Matsubara, N., Geczi, L., ... Cheng, S. Y.(2021). Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

Loriot, Yohann Et Al. "Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Loriot, Yohann Et Al. "Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

Loriot, Y. Et Al. (2021) . "Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

@article{article, author={Yohann Loriot Et Al. }, title={Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}